Incidence of gynaecomastia in Klinefelter syndrome adolescents and outcome of testosterone treatment.
Adolescent gynaecomastia
Hypogonadism
Klinefelter syndrome
Testosterone treatment
Journal
European journal of pediatrics
ISSN: 1432-1076
Titre abrégé: Eur J Pediatr
Pays: Germany
ID NLM: 7603873
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
25
11
2020
accepted:
15
04
2021
revised:
23
03
2021
pubmed:
3
5
2021
medline:
14
9
2021
entrez:
2
5
2021
Statut:
ppublish
Résumé
The aim was to define the true incidence of gynaecomastia in adolescent boys with Klinefelter syndrome (KS) and to observe testosterone treatment effects on its duration by examination of the prospectively collected data from a specialist referral clinic for boys with KS, with comparison being made with KS boys identified by a historical newborn chromosome screening programme, together with chromosomally normal controls. Fifty-nine boys over age 13 years were referred to a specialist KS clinic; 21 developed gynaecomastia. The comparator was 14 KS boys identified at birth and 94 chromosomally normal control boys. Testosterone was routinely started at the onset of puberty if gynaecomastia, a manifestation of clinical hypogonadism, was present. Oral or transdermal testosterone was administered in the morning, in a reverse physiological rhythm, and doses were increased according to standard pubertal regimens. The incidence of gynaecomastia was not increased in both the KS cohorts compared with controls. The incidence and age of onset of gynaecomastia was 35.6%, at 12.3 (1.8) years in the KS clinic group; 36.0%, at 13.7 (0.6) years in the newborn survey group; and 34.0%, at 13.6 (0.8) years in the controls. Full resolution of the gynaecomastia occurred in the 12/14 KS clinic boys on testosterone treatment who had completed puberty and as long as adherence was maintained.Conclusion: The incidence of gynaecomastia in KS boys (overall 35.6%) is not increased over typically developing boys. Commencing testosterone when gynaecomastia develops with physiological dose escalation and full adherence can result in the resolution of the gynaecomastia. What is Known: • Gynaecomastia is a common feature in Klinefelter syndrome men. • Hypogonadism occurs from mid-puberty onwards with the absence of the usual rise in testosterone levels. What is New: • The incidence of pubertal gynaecomastia in Klinefelter syndrome is not different from typically developing boys. • Early and prompt starting of testosterone gel treatment and increasing the dose physiologically may help to resolve the gynaecomastia without the need for surgery.
Identifiants
pubmed: 33934233
doi: 10.1007/s00431-021-04083-2
pii: 10.1007/s00431-021-04083-2
doi:
Substances chimiques
Testosterone
3XMK78S47O
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3201-3207Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Klinefelter HF, Reifenstein EC, Albright F (1942) Syndrome characterised by gynecomastia, aspermatogenesis without a-leydigism, and increased secretion of follicle stimulating hormone. J Clin Endocrinol 11:615–627
doi: 10.1210/jcem-2-11-615
Ratcliffe SG, Butler GE, Jones M (1990) Edinburgh study of growth and development of children with sex chromosome abnormalities IV. Birth Defects Orig Artic Ser 26(4):1–44
pubmed: 2090314
Nielsen J, Wohlert M (1990) Sex chromosome abnormalities found among 34,910 newborn children: Results from a 13-year incidence study in Arhus, Denmark. Birth Defects Orig Artic Ser 26(4):209–223
pubmed: 2090319
Stewart DA, Bailey JD, Netley CT, Rovet J, Park E (1982) Growth and development from early to midadolescence of children with X and Y chromosome aneuploidy: the Toronto Study. Birth Defects Orig Artic Ser 22(3):119–182
Stewart DA, Bailey JD, Netley CT, Park E (1990) Growth, development and behavioural outcome from mid-adolescence to adulthood in subjects with chromosome aneuploidy: the Toronto study. Birth Defects Orig Artic Ser 26(4):131–188
pubmed: 2090316
Robinson A, Bender B, Linden MG, Salbenblatt JS (1990). Sex chromosome aneuploidy: the Denver study. Birth Defects Orig Artic Ser 26(4):59–115
Smyth CS, Bremner WJ (1998) Klinefelter syndrome. Arch Intern Med 158:1309–1316
doi: 10.1001/archinte.158.12.1309
Aksglaede L, Skakkebaek NE, Almstrup K, Juul A (2011) Clinical and biological parameters in 166 boys, adolescents and adults with nonmosaic Klinefelter syndrome: a Copenhagen experience. Acta Paediatr 100(6):793–806
doi: 10.1111/j.1651-2227.2011.02246.x
Salbenblatt JA, Bender BG, Puck MH, Robinson A, Faiman C, Winter JS (1985) Pituitary-gonadal function in Klinefelter syndrome before and during puberty. Pediatr Res 19(1):82–86
doi: 10.1203/00006450-198501000-00022
Topper E, Dickerman Z, Prager-Lewin R, Kaufman H, Maimon Z, Laron Z (1982) Puberty in 24 patients with Klinefelter syndrome. Eur J Pediatr 139(1):8–12
doi: 10.1007/BF00442070
Nielsen J, Pelsen B, Sorensen K (1988) Follow up of 30 Klinefelter males treated with testosterone. Clin Genet 33:262–269
doi: 10.1111/j.1399-0004.1988.tb03447.x
Davis SM, Rogol AD, Ross JL (2015) Testis development and fertility potential in boys with Klinefelter syndrome. Endocrinol Metab Clin N Am 44(4):843–865
doi: 10.1016/j.ecl.2015.07.008
Davis S, Howell S, Wilson R, Tanda T, Ross J, Zeitler P, Tartaglia N (2016) Advances in the interdisciplinary care of children with Klinefelter syndrome. Adv Pediatr Infect Dis 63(1):15–46
Flannigan R, Patel P, Paduch DA (2018) Klinefelter syndrome. The effects of early androgen therapy on competence and behavioral phenotype. Sex Med Rev 6(4):595–606
doi: 10.1016/j.sxmr.2018.02.008
Butler GE, Sellar RE, Walker RF, Hendry M, Kelnar CJH, Wu FCW (1992) Oral testosterone undecanoate in the management of delayed puberty in boys: pharmacokinetics and effects on sexual maturation and growth. J Clin Endocrinol Metab 75:37–44
pubmed: 1619029
Rogol AD, Swerdloff RS, Reiter EO (2014) A multicenter, open-label, observational study of testosterone gel (1%) in the treatment of adolescent boys with Klinefelter syndrome or Anorchia. J Adolesc Health 54(1):20–25
doi: 10.1016/j.jadohealth.2013.07.021
British Society for Paediatric Endocrinology and Diabetes clinical guidelines https://www.bsped.org.uk/media/1659/revised-bsped-testosterone-guideline-4th-draft-30072019.pdf
Ratcliffe SG, Bancroft J, Axworthy D, McLaren W (1982) Klinefelter’s syndrome in adolescence. Arch Dis Child 57(1):6–12
pubmed: 7065696
pmcid: 2863282
Mieritz MG, Rakêt LL, Hagen CP, Nielsen JE, Talman ML, Petersen JH, Sommer SH, Main KM, Jørgensen N, Juul A (2015) A longitudinal study of growth, sex steroids, and igf-1 in boys with physiological gynecomastia. J Clin Endocrinol Metab 100(10):3752–3759
doi: 10.1210/jc.2015-2836
Soliman AT, De Sanctis V, Yassin M (2017) Management of adolescent gynecomastia: an update. Acta Biomed 88(2):204–213
pubmed: 28845839
Large DM, Anderson DC (1979) Twenty-four hour profiles of circulating androgens and oestrogens in male puberty with and without gynaecomastia. Clin Endocrinol 11:505–521
doi: 10.1111/j.1365-2265.1979.tb03103.x
Reinehr T, Kulle A, Barth A, Ackermann J, Lass N, Holterhus P-M (2020) Sex hormone profile in pubertal boys with gynecomastia and pseudogynecomastia. J Clin Endocrinol Metab 105(4):dgaa044
doi: 10.1210/clinem/dgaa044
Ruvalcaba RH (1989) Testosterone therapy in Klinefelter’s syndrome (a prolonged observation). Andrologia 21(6):535–541
doi: 10.1111/j.1439-0272.1989.tb02467.x